结直肠癌治疗的新视角,MicroRNAs 的作用。

IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Victoria A Belova, Liudmila V Spirina, Alexandra V Avgustinovich, Sergey G Afanas'ev, Maxim Y Volkov, Daniil I Azovsky, Alexander M Volkov, Tatyana S Klyushina
{"title":"结直肠癌治疗的新视角,MicroRNAs 的作用。","authors":"Victoria A Belova, Liudmila V Spirina, Alexandra V Avgustinovich, Sergey G Afanas'ev, Maxim Y Volkov, Daniil I Azovsky, Alexander M Volkov, Tatyana S Klyushina","doi":"10.2174/0113894501304351240703113651","DOIUrl":null,"url":null,"abstract":"<p><p>The main epidemiological and clinical data on colorectal cancer, as well as the features of molecular pathology, are discussed in the literature review. Efforts are being putto identify promising targets, particularly small non-coding nucleotide sequences, which can lead to new treatments for this disease. The discovery of significant mutations that contribute to the development of colorectal tumors is a major step in the advancement of molecular oncology, as these mutations give rise to heterogeneous tumors that differ in their origin. These mutations play a significant role in the progression of the disease and are now being targeted for treatment. The prognosis for a disease is influenced by the patient's sensitivity to antitumor therapy. However, new approaches to finding effective targets for antitumor treatments face new fundamental challenges due to clinical issues. These issues include the epigenetic regulation of markers of oncogenesis, which allows for the development of new therapeutic strategies. RNA interference, in particular, has been linked to non-copying RNA sequences such as microRNAs. These microRNAs are associated with certain processes that can influence all aspects of oncogenesis. The diversity of microRNAs allows for a differentiated approach when treating tumors in various locations.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"715-723"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs.\",\"authors\":\"Victoria A Belova, Liudmila V Spirina, Alexandra V Avgustinovich, Sergey G Afanas'ev, Maxim Y Volkov, Daniil I Azovsky, Alexander M Volkov, Tatyana S Klyushina\",\"doi\":\"10.2174/0113894501304351240703113651\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The main epidemiological and clinical data on colorectal cancer, as well as the features of molecular pathology, are discussed in the literature review. Efforts are being putto identify promising targets, particularly small non-coding nucleotide sequences, which can lead to new treatments for this disease. The discovery of significant mutations that contribute to the development of colorectal tumors is a major step in the advancement of molecular oncology, as these mutations give rise to heterogeneous tumors that differ in their origin. These mutations play a significant role in the progression of the disease and are now being targeted for treatment. The prognosis for a disease is influenced by the patient's sensitivity to antitumor therapy. However, new approaches to finding effective targets for antitumor treatments face new fundamental challenges due to clinical issues. These issues include the epigenetic regulation of markers of oncogenesis, which allows for the development of new therapeutic strategies. RNA interference, in particular, has been linked to non-copying RNA sequences such as microRNAs. These microRNAs are associated with certain processes that can influence all aspects of oncogenesis. The diversity of microRNAs allows for a differentiated approach when treating tumors in various locations.</p>\",\"PeriodicalId\":10805,\"journal\":{\"name\":\"Current drug targets\",\"volume\":\" \",\"pages\":\"715-723\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113894501304351240703113651\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501304351240703113651","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

文献综述讨论了结直肠癌的主要流行病学和临床数据以及分子病理学特征。目前正在努力确定有希望的靶点,特别是小的非编码核苷酸序列,这些靶点可以为这种疾病带来新的治疗方法。发现导致结直肠肿瘤发生的重要突变是分子肿瘤学发展的重要一步,因为这些突变会导致起源不同的异质性肿瘤。这些突变在疾病的发展过程中起着重要作用,目前正成为治疗的靶点。患者对抗肿瘤治疗的敏感性影响着疾病的预后。然而,由于临床问题,寻找抗肿瘤治疗有效靶点的新方法面临着新的基本挑战。这些问题包括肿瘤发生标志物的表观遗传学调控,这为开发新的治疗策略提供了可能。RNA 干扰尤其与 microRNA 等非复制 RNA 序列有关。这些 microRNA 与某些可影响肿瘤发生各个方面的过程有关。由于微RNA的多样性,在治疗不同部位的肿瘤时可以采用不同的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs.

The main epidemiological and clinical data on colorectal cancer, as well as the features of molecular pathology, are discussed in the literature review. Efforts are being putto identify promising targets, particularly small non-coding nucleotide sequences, which can lead to new treatments for this disease. The discovery of significant mutations that contribute to the development of colorectal tumors is a major step in the advancement of molecular oncology, as these mutations give rise to heterogeneous tumors that differ in their origin. These mutations play a significant role in the progression of the disease and are now being targeted for treatment. The prognosis for a disease is influenced by the patient's sensitivity to antitumor therapy. However, new approaches to finding effective targets for antitumor treatments face new fundamental challenges due to clinical issues. These issues include the epigenetic regulation of markers of oncogenesis, which allows for the development of new therapeutic strategies. RNA interference, in particular, has been linked to non-copying RNA sequences such as microRNAs. These microRNAs are associated with certain processes that can influence all aspects of oncogenesis. The diversity of microRNAs allows for a differentiated approach when treating tumors in various locations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current drug targets
Current drug targets 医学-药学
CiteScore
6.20
自引率
0.00%
发文量
127
审稿时长
3-8 weeks
期刊介绍: Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信